Ipamorelin Research for Growth Hormone Release
An evidence-based overview of research examining Ipamorelin in the context of growth hormone release. This page synthesizes findings from peer-reviewed literature.
Research Summary
Ipamorelin was designed by Novo Nordisk as a selective growth hormone secretagogue with minimal effects on cortisol and prolactin. Human studies demonstrate dose-dependent GH release through ghrelin receptor (GHS-R1a) activation. The key advantage over older GH secretagogues (GHRP-6, GHRP-2) is selectivity - ipamorelin produces GH release without the cortisol elevation, prolactin increase, or appetite stimulation seen with less selective agents. Clinical development was discontinued after Phase 2 trials for post-operative ileus failed to show efficacy. The peptide is not approved for any indication but remains studied in research contexts.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Growth Hormone Release
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Ipamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.